Skip to content

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

January 8, 2025

New Releases from NCBI BookshelfTirzepatide (type 2 diabetes mellitus): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-112 [Internet].Tirzepatide (type 2 diabetes mellitus): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-112 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfPolatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-141 [Internet].Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-141 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfIdecabtagene vicleucel (multiple myeloma, ≥ 2 prior therapies): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-35 [Internet].Idecabtagene vicleucel (multiple myeloma, ≥ 2 prior therapies): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-35 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfEmpagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal).Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal).

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfApplying lessons learned from the COVID-19 pandemic to future clinical trials: ASPE Commentary [Internet].Applying lessons learned from the COVID-19 pandemic to future clinical trials: ASPE Commentary [Internet].

Leave a Comment / Uncategorized / admin

In 2023, ASPE launched a research project to understand the impacts of COVID-19 on the clinical trial enterprise and identify

New Releases from NCBI BookshelfDostarlimab (endometrial cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-143 [Internet].Dostarlimab (endometrial cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-143 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfBest Practices for COVID-19 Testing and Vaccination: Findings from the COVID-19 Best Practices National Survey [Internet].Best Practices for COVID-19 Testing and Vaccination: Findings from the COVID-19 Best Practices National Survey [Internet].

Leave a Comment / Uncategorized / admin

This report presents findings from the National Survey on Best Practices for COVID-19 Vaccination and Testing, part of the Best

New Releases from NCBI BookshelfComparing Ways to Increase Hepatitis B and C Screening among Asian Americans [Internet].Comparing Ways to Increase Hepatitis B and C Screening among Asian Americans [Internet].

Leave a Comment / Uncategorized / admin

Liver cancer and hepatitis B (HBV) are significant health disparities for Asian Americans, and little is known about hepatitis C

New Releases from NCBI BookshelfBrolucizumab (neovascular age-related macular degeneration): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-101 [Internet].Brolucizumab (neovascular age-related macular degeneration): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-101 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfUblituximab (multiple sclerosis): Benefit assessment according to §35a SGB V,: IQWiG Reports – Commission No. A24-13 [Internet].Ublituximab (multiple sclerosis): Benefit assessment according to §35a SGB V,: IQWiG Reports – Commission No. A24-13 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top